Literature DB >> 10668690

Idiopathic intracranial hypertension: relationship to depression, anxiety, and quality of life.

J J Kleinschmidt1, K B Digre, R Hanover.   

Abstract

OBJECTIVE: To explore the incidence of depression and anxiety and to measure quality of life in women with idiopathic intracranial hypertension (IIH), a matched group cross-sectional study was conducted. Women with IIH (n = 28) were compared with control groups of weight- and age-matched women not diagnosed with IIH (n = 30) and with age-matched women of normal weight (n = 30).
METHODS: Eighty-eight women completed a questionnaire soliciting health information and standardized questionnaires measuring depression, anxiety, and quality of life. The groups were compared using analysis of variance and chi2 tests. Where appropriate, post hoc comparisons were made using Fisher's test.
RESULTS: Patients with IIH reported a greater number of adverse health problems than either of the control groups. Non-health-related psychosocial concerns were equally prevalent among the three groups, but IIH patients were significantly more affected by hardships associated with health problems than the other two groups. The patient group also had higher levels of depression and anxiety than the control groups. These adverse health conditions were reflected in decreased quality of life measures for the IIH patients.
CONCLUSIONS: This study supports previous reports that link obesity and psychosocial difficulties, but obesity alone is not the explanation for the higher levels of depression and lower levels of quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 10668690     DOI: 10.1212/wnl.54.2.319

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

Review 1.  New developments in idiopathic intracranial hypertension.

Authors:  R K Shin; L J Balcer
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

2.  Acetazolamide for pseudotumor cerebri: evidence from the NORDIC trial.

Authors:  Jonathan C Horton
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

3.  The idiopathic intracranial hypertension treatment trial: clinical profile at baseline.

Authors:  Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

4.  Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results.

Authors:  Kathleen B Digre; Beau B Bruce; Michael P McDermott; Kristin M Galetta; Laura J Balcer; Michael Wall
Journal:  Neurology       Date:  2015-05-20       Impact factor: 9.910

5.  Idiopathic Intracranial Hypertension.

Authors:  Robert K. Shin; Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

Review 6.  Idiopathic intracranial hypertension headache.

Authors:  Kathleen B Digre
Journal:  Curr Pain Headache Rep       Date:  2002-06

7.  Psychiatric symptoms are frequent in idiopathic intracranial hypertension patients.

Authors:  Matheus Fernandes de Oliveira; R H G Yamashita; A A Boa Sorte; J M Rotta; K A Norremose; M J Teixeira; F C G Pinto
Journal:  Neurosurg Rev       Date:  2020-05-26       Impact factor: 3.042

Review 8.  Pseudotumor cerebri: brief review of clinical syndrome and imaging findings.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-16       Impact factor: 3.825

Review 9.  The diagnosis and management of idiopathic intracranial hypertension and the associated headache.

Authors:  Rigmor Højland Jensen; Aleksandra Radojicic; Hanne Yri
Journal:  Ther Adv Neurol Disord       Date:  2016-03-21       Impact factor: 6.570

10.  A comparison of idiopathic intracranial hypertension with and without papilledema.

Authors:  Kathleen B Digre; Beau K Nakamoto; Judith E A Warner; Wendy J Langeberg; Susan K Baggaley; Bradley J Katz
Journal:  Headache       Date:  2009-02       Impact factor: 5.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.